Fortune 100 diversified medical products and pharmaceuticals organization
As part of a corporate separation, a Fortune 100 diversified medical products and research-based pharmaceuticals organization needed to separate its PharmacoVigilance (PV) processes and systems between the two new corporate entities.
Peritius was engaged to manage the separation of the firm’s PV medical functions, PV systems support function, and PV and medical communications systems and data. To support this effort, Peritius:
The client required that on Day 1 both corporate entities meet regulatory reporting commitments for drug safety and that transitional service agreements (TSA) were established to provide ongoing operations support through the separation.
Both PV organizations were provisioned for short- and long-term success. On Day 1 both corporate entities met regulatory reporting commitments for drug safety. The client’s plan for TSA termination by 24 months after Day 1 was on schedule. All expected benefits were met and the transition office requirements were satisfied.
Peritius delivers game-changing outcomes. We’re a management consulting firm that untangles project complexity and accelerates strategy. Contact us today to see how we can help.
EDWOSB (Women-Owned Small Business) Federal Designation
Women’s Business Enterprise (WBE) City of Chicago and State of Illinois